本帖最后由 StephenW 于 2011-11-4 08:18 编辑
Tenofovir Effective in Treating Patients with Entecavir Resistance[poor response]
While entecavir and tenofovir are considered the best available antivirals and are recommended as first-treatment options, 3% of patients treated with entecavir don’t respond to treatment.
Researchers tried treating 14 of the patients who had not responded to entecavir with tenofovir to see if that drug would be effective in these patients. The patients were Chinese, predominantly male, HBeAg-positive, and infected with either genotype C (71%) or B (29%).
After 65 weeks of treatment with tenofovir, all 14 patients achieved undetectable HBV-DNA and normal ALT levels. Two of 12 HBeAg-positive lost HBeAg and developed “e” antibodies over 80 weeks of treatment. None of the tenofovir-treated patients failed to respond to treatment.
“In conclusion,” researchers wrote in the Journal of Viral Hepatitis, “suboptimal response to entecavir is rare (approximately3%). Tenofovir is safe and very effective in the management of HBV patients with (poor response) to entecavir.”
| 
发表于 2011-11-4 08:18
